Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer
文献类型：期刊论文
| 作者 | Huang, Jian1; Shao, Xiying1; Cai, Li2; Shi, Yanxia3; Chen, Zhanhong1; Huang, Ping1; Yin, Yongmei4; Zhang, Lili5; Shen, Peng6; Cao, Wenming1 |
| 刊名 | CANCER RESEARCH
 |
| 出版日期 | 2021-02-01 |
| 卷号 | 81 |
| ISSN号 | 0008-5472 |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | AMER ASSOC CANCER RESEARCH |
| WOS记录号 | WOS:000618737700409 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/120418]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 2.Harbin Med Univ, Dept Breast Med Oncol, Canc Hosp, Harbin, Peoples R China 3.Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China 4.Nanjing Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanjing, Peoples R China 5.Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Jiangsu Canc Hosp,Jiangsu Inst Canc Res, Nanjing, Peoples R China 6.Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Huang, Jian,Shao, Xiying,Cai, Li,et al. Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer[J]. CANCER RESEARCH,2021,81. |
| APA | Huang, Jian.,Shao, Xiying.,Cai, Li.,Shi, Yanxia.,Chen, Zhanhong.,...&Wang, Xiaojia.(2021).Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer.CANCER RESEARCH,81. |
| MLA | Huang, Jian,et al."Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer".CANCER RESEARCH 81(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。